Future Directions in Smart Prostate Cancer Screening – Highlights from the 6th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer

Posted by Faina Shtern, MD | Aug 2023

Faina Shtern, MD, presented “Future Directions in Smart Prostate Cancer Screening – Highlights from the 6th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer” during the 33rd International Prostate Cancer Update on January 24, 2023, in Vail, Colorado.

How to cite: Shtern, Faina. “Future Directions in Smart Prostate Cancer Screening – Highlights from the 6th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer.” January 24, 2023. Accessed May 2024. https://grandroundsinurology.com/future-directions-in-smart-prostate-cancer-screening-highlights-from-the-6th-annual-global-summit-on-precision-diagnosis-and-treatment-of-prostate-cancer/

Future Directions in Smart Prostate Cancer Screening – Highlights from the 6th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer – Summary

Faina Shtern, MD, discusses future directions in smart prostate cancer screening and highlights from the Sixth Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer. Dr. Shtern explains prostate-specific antigen (PSA) screening for prostate cancer and guidelines for reducing risks associated with it. She mentions “smart” PSA screening, and she stresses the importance of novel quantitative approaches to risk management.

Dr. Shtern outlines advances in noninvasive diagnostic tools such as liquid biomarkers, testing for germline mutations in men with family history, and imaging. She displays a list of major international clinical trials studying integration of PSA, liquid biomarkers, and MRI and summarizes the ongoing PROBASE and BARCODE 1 trials, which may help define the role of genetic profiling in targeted screening.

Dr. Shtern outlines the IP1 PROSTAGRAM Study comparing MRI, PSA, and ultrasound. She reviews major international clinical trials studying integration of PSA, liquid biomarkers, and MRI (e.g., REIMAGINE Study).

She addresses micro ultrasound (microUS), explaining it provides improved visualization vs. standard US, has comparable diagnostic accuracy to MRI, and is supported by institutional series as an option to MRI-US fusion prostate biopsy. She cites the ongoing OPTIMUM trial seeking to confirm equivalence with MRI in a randomized prospective study and evaluate the benefit of adding MRI fusion to microUS prostate biopsy.

Finally, Dr. Shtern discusses a study on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging, examining combined MRI/PET before prostate cancer diagnosis, explaining it may improve differentiation of GG1 vs. GG2 disease but emphasizing the need for further research.

About The 33rd Annual International Prostate Cancer Update:

The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 33rd iteration of the meeting occurred January 22-25, 2023 in Vail, Colorado. To view more educational presentations from IPCU 33, visit our collection page.

About The Author

Faina Shtern, MD

Faina Shtern, MD, is the President and CEO of AdMeTech Foundation, a non-profit dedicated to ending the prostate cancer crisis. As a Founder of AdMeTech, Faina Shtern, MD, has been leading groundbreaking programs in prostate cancer research, education, awareness and advocacy, with a focus on the advancement of precision diagnostics and their integration with precision treatment, since 1997. This work has led to: a) Development, global PI-RADS standardization, clinical evaluation, and implementation of precision MRI; b) Establishment of molecular imaging, with priority focus on PSMA PET; c) Original work in robotics for precision biopsy and treatment; d) Recognition and expansion of radiogenomics; and e) Precedent-setting legislation in US Congress and Massachusetts. Prior to founding AdMeTech, Dr. Shtern served as Chief of the Diagnostic Imaging Research Branch at the National Cancer Institute, and Associate Director for Science and Technology, Office of Women’s Health, Office of the Secretary, US Department of Health and Human Services. She also led radiology research at Harvard Medical School’s Beth Israel Deaconess Medical Center and at Boston Children’s Hospital between 1999 and 2008. Dr. Shtern has led and participated in numerous scientific and advisory committees, including the Breast Cancer Study Group of the National Academy of Medicine and Vice President Biden’s Cancer Moonshot Program. In 2016, she was named a “Woman of Influence” by the Boston Business Journal.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat